Background: This study aimed to evaluate the efficacy, safety and prognostic factors of
icotinib as first-line treatment in advanced non-small cell lung cancer (NSCLC) patients with …

Purpose This study was conducted to compare the efficacy of a combination of icotinib and
chemotherapy with icotinib or chemotherapy alone in untreated non-small cell lung cancer …

Background: Icotinib is the first generation of epidermal growth factor receptor-tyrosine
kinase inhibitor (EGFR-TKI) independently developed in China, which has been widely used …

Background and objective As the first epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo …

Icotinib is the first oral epidermal growth factor receptor (EGFR) tyrosine kinase receptor
inhibitor, which has been proven to exert significant inhibitory effects on non-small cell lung …

Background The phase 3 ICOGEN trial established the non-inferiority of icotinib to gefitinib
in terms of progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients …

The response to icotinib in advanced non‐small cell lung cancers (NSCLC) with EGFR
uncommon mutation (EGFRum) is unclear. Here we reported the efficacy and potential …

BACKGROUND Icotinib could have potential effect and tolerability when used sequentially
with chemotherapy for advanced epidermal growth factor receptor (EGFR)-mutated non …

Icotinib is a novel and the third listed epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), which exerts a good anti-tumor efficacy on non-small cell lung …

Background and objective Several clinical trials have proven that icotinib hydrochloride, a
novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits …